The history of kidney transplants stretches back further than most people realize, with the first attempt in a human patient performed in 1933 by Ukrainian surgeon Yurii Voronoy. That graft failed almost immediately, and it took another two decades of research before a kidney transplant actually kept someone alive long-term. The milestone that changed everything came on December 23, 1954, when a surgical team in Boston transplanted a kidney between identical twin brothers, and the recipient survived for years. Between those two dates, and in the decades after, the story of kidney transplantation touches on nearly every major advance in modern surgery, immunology, and drug development.
The Surgical Groundwork Before Any Transplant Was Possible
Before anyone could move an organ from one body to another, surgeons needed a reliable way to reconnect blood vessels. That problem was solved in the early 1900s by French surgeon Alexis Carrel, who developed a triangulation suturing technique for joining blood vessels end-to-end. His methods were so effective that they remain in use today, more than a century later.1PubMed. Alexis Carrel (1873-1944): visionary vascular surgeon and pioneer in organ transplantation Carrel won the Nobel Prize in 1912, partly for this work, and his vascular techniques opened the door for every solid organ transplant that would follow.
With blood vessel surgery now feasible, animal experiments in kidney transplantation began in earnest. Researchers learned they could physically transplant a kidney and restore urine output, at least briefly. But these grafts invariably failed within days. Nobody yet understood why, and the concept of immune rejection was still decades away from being properly described. The surgery worked; the biology did not cooperate.
Voronoy’s 1933 Attempt and Why It Failed
Yurii Voronoy, a surgeon working in Kherson, Ukraine, performed the first recorded kidney transplant in a human patient in April 1933.2PubMed. Surgeon Yurii Voronoy (1895-1961) – a pioneer in the history of clinical transplantation His patient was a young woman dying of mercury poisoning-induced kidney failure. Voronoy placed a kidney from a recently deceased donor into her thigh, connecting it to the blood vessels there. The organ never produced urine, and the patient died two days later.
By modern standards, the transplant was doomed from the start. The donor and recipient had incompatible blood types, the organ had been removed hours after the donor’s death, and there was no understanding of how to suppress the immune response. Voronoy performed several more attempts over the following years, but none succeeded. Still, his work established that the operation itself was surgically feasible in humans and inspired other teams around the world to keep trying.
The 1954 Breakthrough Between Identical Twins
The first truly successful kidney transplant happened at Peter Bent Brigham Hospital in Boston on December 23, 1954. Surgeon Joseph Murray, along with urologist Hartwell Harrison and their colleagues, transplanted a kidney from Ronald Herrick into his identical twin brother Richard, who was dying of chronic kidney disease.3PubMed. 1954 Richard lived for eight more years with his new kidney, eventually dying of causes unrelated to the transplant.
The reason this worked when everything before it had failed was genetic. Because the Herrick brothers were identical twins, their tissues were immunologically indistinguishable. Richard’s immune system recognized Ronald’s kidney as “self” and left it alone. The team had spent years preparing for this moment, performing skin grafts between the twins to confirm they would not reject each other’s tissue before attempting the kidney operation. Murray would later receive the Nobel Prize in Physiology or Medicine in 1990 for this work.
The success was thrilling, but it also highlighted the central problem. Identical twins are rare, and most people who need a kidney do not have one. For transplantation to become widely useful, surgeons needed a way to prevent the recipient’s immune system from attacking a genetically foreign organ.
Understanding Immune Rejection
The scientific framework for understanding why transplants failed came from immunology research in the 1940s and 1950s. Work by Peter Medawar and others demonstrated that graft rejection was an immune response, not simply a failure of surgical technique. The body’s immune system evolved to recognize and destroy foreign cells, and a transplanted organ from an unrelated donor is, from the immune system’s perspective, an invader.
This insight reframed the entire transplant problem. It was no longer a surgical challenge; the surgical methods Carrel had pioneered decades earlier worked perfectly well. The challenge was immunological. Could you somehow trick or suppress the immune system enough that it would tolerate a foreign kidney without destroying the recipient’s ability to fight off infections?
Early Immunosuppression and the Drug That Changed Everything
The first attempts at suppressing the immune system to enable transplants were blunt instruments. Total body irradiation was used in the late 1950s to wipe out a recipient’s immune response before transplantation. It sometimes worked, but it also left patients dangerously vulnerable to infections. The approach was not sustainable.
A major advance came in the early 1960s with azathioprine, one of the first drugs used specifically to prevent organ rejection. Combined with steroids like prednisone, azathioprine formed the backbone of transplant immunosuppression for roughly two decades. It made transplants between unrelated donors and recipients survivable for the first time, though rejection and infection remained common problems. Azathioprine was eventually supplanted in most transplant regimens by mycophenolate starting in the 1990s, after clinical trials suggested better outcomes with the newer drug.4PubMed Central. Case Report: Azathioprine: An Old and Wronged Immunosuppressant
But the real game-changer arrived in the late 1970s with cyclosporine, a compound originally derived from a soil fungus. Cyclosporine was far more targeted than previous drugs, suppressing the specific arm of the immune system responsible for rejecting transplants while leaving other immune functions more intact. Its introduction into clinical practice transformed outcomes: two-year graft survival jumped to more than 80 percent.5PubMed. Impact of cyclosporine on the development of immunosuppressive therapy Cyclosporine improved rates of acute rejection and early graft survival dramatically, though long-term data on whether it extended graft life over many years has been less definitive.6PubMed Central. Cyclosporine: a review Nonetheless, its introduction is widely regarded as the single most important pharmacological breakthrough in transplant medicine.
Tissue Matching and Compatibility
Alongside drug development, researchers refined the science of matching donors and recipients. The human leukocyte antigen (HLA) system, a set of proteins on the surface of cells that the immune system uses to distinguish “self” from “foreign,” became the centerpiece of compatibility testing. The better the HLA match between donor and recipient, the lower the risk of rejection.
For decades, matching was done at the antigen level, a relatively coarse way of comparing donor and recipient tissues. More recently, researchers have proposed molecular-level matching methods that are far more granular, looking at specific amino acid differences between HLA molecules rather than simply classifying them into broad antigen types.7PubMed Central. The Progress and Challenges of Implementing HLA Molecular Matching in Clinical Practice These newer approaches are still being implemented in clinical practice, but they hold the potential to better predict which donor-recipient pairs will have the best outcomes and which are at higher risk for rejection.
In practice, perfect HLA matching between unrelated people is unusual. Modern immunosuppressive drugs are good enough that transplants routinely succeed even with imperfect matches, but a closer match still generally means a kidney lasts longer and requires less aggressive medication to maintain.
How Organ Preservation Improved
A transplanted kidney faces a ticking clock. From the moment it loses its blood supply in the donor, the organ begins to deteriorate. Minimizing this damage has been a persistent challenge in transplant medicine.
For much of transplant history, the standard approach was static cold storage: the kidney is flushed with a preservation solution and placed on ice. Cold temperatures slow metabolism and buy time, but the organ still suffers damage from the lack of blood flow. The development of specialized preservation solutions in the 1960s and 1970s extended the window during which a kidney could be stored and still function after transplantation, from a few hours to roughly 24 to 36 hours in most cases.
A more advanced technique, hypothermic machine perfusion, continuously pumps a cold preservation solution through the organ’s blood vessels during storage. This approach has several advantages: it keeps the vascular bed open, delivers nutrients and a small amount of oxygen to the tissue, removes metabolic waste products, and even allows clinicians to assess the organ’s viability before surgery.8PubMed Central. Current state of hypothermic machine perfusion preservation of organs: The clinical perspective Machine perfusion has also been used to rescue kidneys from donors that would previously have been considered too marginal to use, expanding the donor pool.9PubMed. Perspectives in organ preservation Newer systems that perfuse organs at body temperature, rather than on ice, are now being studied as a way to further reduce preservation-related damage.
Laparoscopic Surgery and the Living Donor Revolution
For the first several decades of transplantation, removing a kidney from a living donor meant a large open incision, significant postoperative pain, and a recovery period of several weeks. In 1995, a team performed the first laparoscopic live donor nephrectomy, using small incisions and a camera to guide the surgery.10PubMed. Laparoscopic live donor nephrectomy The donor experienced minimal discomfort and went home the next day.
The impact of this technique on the field was enormous. Laparoscopic donor nephrectomy reduced donor morbidity without compromising the quality of the harvested kidney, and it became the preferred method at many transplant centers worldwide.11PubMed Central. Laparoscopic Live Donor Nephrectomy: Trends in Donor and Recipient Morbidity Following 381 Consecutive Cases The shorter recovery and smaller scars made living donation considerably less daunting for potential donors, contributing to an increase in the number of people willing to donate. This mattered because kidneys from living donors generally last longer than those from deceased donors, making every additional living donor especially valuable.
Kidney Paired Donation and Swap Programs
Even when a willing living donor steps forward, their kidney may be incompatible with their intended recipient due to blood type differences or a positive crossmatch, meaning the recipient has pre-formed antibodies against the donor’s tissue. For years, these pairs were simply out of luck.
Kidney paired donation, or KPD, solved this by matching incompatible pairs with each other. If Patient A’s donor is compatible with Patient B, and Patient B’s donor is compatible with Patient A, the donors swap recipients and both patients receive a transplant. The concept expanded further through chain donations, in which a single altruistic donor who has no specific intended recipient triggers a chain of transplants across multiple incompatible pairs. From 2007 to 2014, one U.S. registry alone facilitated 243 transplants through such exchanges, with roughly two-thirds occurring through extended chain donations rather than simple two-way swaps.12PubMed Central. Historical Matching Strategies in Kidney Paired Donation: The 7-Year Evolution of a Web-Based Virtual Matching System
Programs in Europe have also tackled this challenge. A Dutch exchange program registered over a hundred incompatible pairs, including both blood type-incompatible and crossmatch-positive combinations, and ran regular matching rounds to create new compatible pairings.13PubMed. Living donor kidney exchange for both ABO-incompatible and crossmatch positive donor-recipient combinations Crossmatch-positive pairs turned out to be significantly easier to match than blood type-incompatible pairs in these programs. Today, kidney paired donation registries operate in many countries and have collectively enabled thousands of transplants that would otherwise never have happened.
List exchange programs have added another dimension. In a list exchange, the donor from an incompatible pair gives their kidney to someone on the deceased donor waiting list, and in return, their intended recipient receives priority for the next compatible deceased donor kidney.14PubMed. Utilizing list exchange and nondirected donation through ‘chain’ paired kidney donations Integrating list exchanges with paired donation and chain donation has created a flexible system that maximizes the number of transplants from any given pool of willing donors.
Animal-to-Human Transplants, Then and Now
The idea of using animal organs to solve the organ shortage is almost as old as transplantation itself. In 1963 and 1964, surgeon Keith Reemtsma transplanted chimpanzee kidneys into 13 patients when human organs were unavailable and chronic dialysis was not yet a practical alternative. One of those patients returned to work for nearly nine months before dying suddenly from what was believed to be an electrolyte disturbance, not organ rejection.15PubMed Central. A brief history of cross-species organ transplantation That result was remarkable for its era, but the approach was abandoned as human organ donation increased and dialysis became widely available.
Xenotransplantation, as animal-to-human transplantation is called, has returned with force in recent years thanks to gene-editing technology. Pigs are the preferred donor species because their organs are similar in size to human organs and they can be bred in large numbers. The problem has always been that pig cells carry sugar molecules on their surfaces that trigger immediate, violent rejection in humans. CRISPR-Cas9 gene editing now allows researchers to knock out the genes responsible for those sugars, insert human genes that help regulate the immune response, and deactivate pig retroviruses that could otherwise pose an infection risk.16Theoretical and Natural Science. CRISPR-Cas9-Mediated Genetic Modifications in Pig-to-Human Xenotransplantation Multiple pig-to-human kidney transplants have now been performed in clinical settings, and early results have shown that genetically modified pig kidneys can function in human recipients without immediate rejection. Whether these organs can last for years, as a well-matched human kidney can, remains to be seen.
How Long Transplanted Kidneys Last Today
Modern kidney transplant outcomes would have been unimaginable to the surgeons of the 1950s. A kidney from a living donor now lasts a median of roughly 15 to 20 years, while kidneys from deceased donors typically function for about 10 to 15 years, though individual outcomes vary widely depending on how well the tissue was matched, how faithfully the recipient takes immunosuppressive medications, and the recipient’s overall health.
Immunosuppressive regimens have become more sophisticated since the cyclosporine era. Today’s standard protocols typically combine multiple drugs that target different parts of the immune response, allowing lower doses of each and fewer side effects than any single drug at a high dose would cause. Tacrolimus, which works through a mechanism similar to cyclosporine but is more potent, replaced cyclosporine as the cornerstone of most regimens in the late 1990s. Newer agents continue to be developed, with the long-term goal of inducing tolerance, a state in which the recipient’s immune system accepts the transplanted organ without any ongoing medication. True tolerance has been achieved in a small number of experimental cases but is not yet standard practice.
One persistent challenge is chronic rejection, a slow, progressive process in which the immune system gradually damages the transplanted kidney over months or years despite immunosuppression. Chronic rejection, along with the side effects of lifelong immunosuppressive therapy itself, remains the primary reason transplanted kidneys eventually fail. Research into better biomarkers for early detection of chronic rejection, and into drugs that might halt or reverse it, is one of the most active areas in transplant medicine.
The Organ Shortage That Drives Innovation
Despite every advance described above, the fundamental problem in kidney transplantation remains the gap between supply and demand. In the United States alone, more than 90,000 people are on the waiting list for a kidney at any given time, while only about 25,000 kidney transplants are performed each year. Wait times of five years or more are common, and thousands of people die each year while waiting.
This shortage is the engine behind nearly every innovation in the field. Paired donation programs, machine perfusion of marginal organs, expanded use of older or medically complex donors, and xenotransplantation all exist because there are not enough healthy human kidneys to go around. It also drives ongoing ethical debates about organ allocation, presumed consent laws (in which everyone is assumed to be an organ donor unless they opt out), and whether financial incentives for living donors should be permitted.
The gap has also pushed researchers toward bioengineering approaches: growing kidneys from stem cells, decellularizing pig kidneys and reseeding them with human cells, or even 3D-printing organ scaffolds. None of these technologies are close to clinical use, but they represent the next potential wave in a field that has been reinventing itself continuously since Alexis Carrel threaded a needle through a blood vessel more than a hundred years ago.